16:00 uur 06-08-2015

Chiltern akkoord over overname van Theorem Clinical Research

LONDEN & WILMINGTON, N.C.–(BUSINESS WIRE)- Chiltern, een toonaangevende aanbieder van uitbesteed onderzoek, heeft vandaag bekendgemaakt dat het een overeenkomst tot overname van branchegenoot Theorem Clinical Research heeft ondertekend.

“Dit is een directe reactie op de vraag naar een onderzoekspartner die op mondiaal niveau sterke operationele en wetenschappelijke kwaliteiten heeft en die flexibel en responsief aanbiedt”, zei Jim Esinhart, ceo van Chiltern. “Deze transactie brengt meer dan 3700 mensen uit meer dan 45 landen bijeen, die allemaal werken onder het motto ‘Ontwikkeld voor Jou’.”

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, welke als enige rechtsgeldig is.

Chiltern Announces Agreement to Acquire Theorem Clinical Research

LONDON & WILMINGTON, N.C.–(BUSINESS WIRE)– Chiltern, a leading global contract research organization (CRO), announced it has signed a purchase agreement to acquire Theorem Clinical Research, another leading global CRO.

“This is a direct response to client demand for a clinical research partner that can provide scientific and operating strengths globally, in a responsive and flexible way,” said Dr. Jim Esinhart, Chiltern CEO. “This transaction will bring together more than 3,700 people in more than 45 countries dedicated to the philosophy of “Designed Around You.”

“Chiltern and Theorem have carved out complementary niches, even across key geographies,” said Dr. John Potthoff, Theorem president and CEO. “In key areas, our capabilities will dovetail into current Chiltern operations — this is a mutually beneficial deal.”

The combined company will operate under the name Chiltern and will gain global reach — most notably in China and Japan — as well as new service offerings for medical devices and diagnostics, clinical analytics and clinical supplies.

The planned transaction between the two organizations is subject to customary regulatory and closing conditions. Both companies will follow antitrust guidelines and continue to function as separate and independent entities until the acquisition is approved. The transaction is expected to close within the next several weeks.

About Chiltern:

Chiltern is a leading global CRO that listens to client needs in order to customize solutions for the biopharma industry. With 34 years in service, Chiltern delivers from three specialized business units: Chiltern Biopharma, with deep therapeutic expertise in respiratory, anti-infectives/vaccines, ophthalmology, dermatology and other specialty areas; Chiltern Oncology, led by physicians, scientists and clinicians to uniquely manage all phases of hematologic and oncologic clinical drug development; and Chiltern Source, a world leader in tailored relationships for FSP, resourcing and staffing solutions. Chiltern’s 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are “Designed Around You.”

Further information is available at: http://www.chiltern.com/.

About Theorem Clinical Research:

Theorem Clinical Research is a global provider of comprehensive clinical services with staff throughout the Americas, Europe and Asia-Pacific and a client base comprised of the world’s leading biopharmaceutical and medical device companies. With industry-leading experts, unparalleled therapeutic expertise and innovative, groundbreaking technology, Theorem is focused on analytic-based development, combination trials and personal data applications to simplify complex trials.


For Chiltern
Lea Studer, +1 308-237-5567
SCORR Marketing

Check out our twitter: @NewsNovumpr